Image courtesy of
In a volatile trading day, three stocks stood out for their significant price movements following earnings reports and corporate updates. Axon Enterprise (Nasdaq: ) saw a substantial surge due to strong AI service demand, while Lyft (Nasdaq: ) and Novo Nordisk (NYSE: ) experienced sharp declines amid disappointing financial results and lowered forecasts.
Axon Enterprise Sees an AI-Driven Surge
Axon Enterprise shares skyrocketed 19.41% to $352.25 by midday, driven by strong demand for its new .
The company, known for supplying Tasers and body cameras to law enforcement, reported second-quarter earnings that beat estimates. Axon’s revenue jumped 34.6% to $504.1 million, with rising 9% to $1.20.
The highlight was Draft One, an AI service launched in April that automates police report writing. CEO Patrick Smith noted that customer response to Draft One was “better than anything I’ve seen,” with the product generating over $100 million in yet-to-be-recorded revenue faster than any other Axon software product. The company raised its full-year revenue outlook to $2-$2.05 billion, up from $1.94-$1.99 billion.
Lyft’s Ride-Sharing Slump
Lyft shares tumbled 11.75% to $9.68 following . The ride-sharing company reported gross bookings of $4.02 billion, falling short of analyst expectations. Its forecast for third-quarter bookings of $4-$4.1 billion also missed the $4.14 billion analyst projection.
Despite posting its first quarterly GAAP profit of $5 million and seeing adjusted earnings more than double to $102.9 million, investors were unimpressed. Lyft did report a 16% increase in rides to restaurants, bars, and entertainment venues, but the overall results suggested softening consumer spending in the gig economy sector.
The company revised its full-year expectation to convert over 90% of adjusted EBITDA to free cash flow, up from its previous guidance of over 70%.
Novo Nordisk’s Weight-Loss Drug Woes
Novo Nordisk (NVO) shares fell 7.85% to $119.91 after the Danish pharmaceutical giant of its weight-loss drug Wegovy.
Second-quarter Wegovy sales grew 55% to 11.66 billion Danish kroner, but this fell short of the 13.54 billion kroner analysts had forecast. Sales of Ozempic, another key product, also narrowly missed expectations. Novo Nordisk reduced its 2024 operating profit forecast to 20-28% growth from the previous 22-30% range, citing “expected, continued periodic supply constraints.”
The company faces increasing competition from rival Eli Lilly’s (NYSE: LLY) drugs Zepbound and Mounjaro in the fast-growing market for weight-loss treatments. Despite the setback, Novo Nordisk slightly raised its sales growth estimate to 22-28% from 19-27%.
